Clinical Trial Update: Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating carboplatin and paclitaxel with or without ramucirumab in thymic carcinoma has completed; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thymic Carcinoma
• Unresectable Thymic Carcinoma

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)
• Ramucirumab (ramucirumab)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Locally Advanced Thymic Carcinoma, Metastatic Thymic Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2025-10-30